TY - JOUR
T1 - Advancements in the identification of EV derived mRNA biomarkers for liquid biopsy of clear cell renal cell carcinomas
AU - Kuczler, Morgan D.
AU - Zieren, Richard C.
AU - Dong, Liang
AU - de Reijke, Theo M.
AU - Pienta, Kenneth J.
AU - Amend, Sarah R.
N1 - Funding Information: The authors thank Tina Wlajnitz and Dr. Phil Pierorazio from the Johns Hopkins University School of Medicine for their contributions in sample collection. We would like to acknowledge the Kiernan Family Fund, who support Dr. Pierorazio's team and RCC projects for the department. The authors thank NanoString Technologies for their expertise and technical support. RC Zieren is supported by Stichting Cure for Cancer foundation, Amsterdam, The Netherlands. Financial Disclosure: KJ Pienta is a consultant for CUE Biopharma, Inc., is a founder and holds equity interest in Keystone Biopharma, Inc., and receives research support from Progenics, Inc. SR Amend also holds equity interest in Keystone Biopharma, Inc. The other authors declare no conflicts of interest. Funding Support: This work was funded by US Department of Defense CDMRP/PCRP (W81XWH-20-10353), the Patrick C. Walsh Prostate Cancer Research Fund and the Prostate Cancer Foundation to SR Amend; and NCI grants U54CA143803, CA163124, CA093900, and CA143055, and the Prostate Cancer Foundation to KJ Pienta. Funding Information: The authors thank Tina Wlajnitz and Dr. Phil Pierorazio from the Johns Hopkins University School of Medicine for their contributions in sample collection. We would like to acknowledge the Kiernan Family Fund, who support Dr. Pierorazio's team and RCC projects for the department. The authors thank NanoString Technologies for their expertise and technical support. RC Zieren is supported by Stichting Cure for Cancer foundation, Amsterdam, The Netherlands. Funding Information: Funding Support: This work was funded by US Department of Defense CDMRP/PCRP (W81XWH-20-10353), the Patrick C. Walsh Prostate Cancer Research Fund and the Prostate Cancer Foundation to SR Amend; and NCI grants U54CA143803, CA163124, CA093900, and CA143055, and the Prostate Cancer Foundation to KJ Pienta. Publisher Copyright: © 2021 The Author(s)
PY - 2022/2
Y1 - 2022/2
N2 - Objective: To propose EV-derived mRNA as a potential diagnostic biomarker detecting the presence of clear cell renal cell carcinoma (ccRCC). There is currently no kidney cancer specific screening or diagnostic technology. Therefore, one-third of kidney cancer diagnoses occur after the cancer has metastasized and is past curative measures Materials and Methods: Urine, plasma, normal tumor adjacent tissue, and tumor tissue was collected from a limited population of ccRCC patients. Extracellular vesicle (EV) isolation was performed on each sample, followed by mRNA extraction from isolated EVs. NanoString nCounter technology was utilized to count the mRNA transcripts present in matched plasma, urine, tumor tissue, and normal tumor adjacent tissue samples. Results: 770 mRNA transcripts related to gene's affecting cancer's progression and metastasis processes were evaluated. Four EV derived mRNA transcripts (ALOX5, RBL2, VEGFA, TLK2) were found specific to urine and tumor tissue samples. Conclusion: Four candidate RCC-specific urine EV biomarkers were identified. However, due to the lack of a true negative control and urine collection techniques, further re-examination is necessary for validation. This study demonstrates the promise of defining disease-specific EV biomarkers in liquid biopsy patient samples.
AB - Objective: To propose EV-derived mRNA as a potential diagnostic biomarker detecting the presence of clear cell renal cell carcinoma (ccRCC). There is currently no kidney cancer specific screening or diagnostic technology. Therefore, one-third of kidney cancer diagnoses occur after the cancer has metastasized and is past curative measures Materials and Methods: Urine, plasma, normal tumor adjacent tissue, and tumor tissue was collected from a limited population of ccRCC patients. Extracellular vesicle (EV) isolation was performed on each sample, followed by mRNA extraction from isolated EVs. NanoString nCounter technology was utilized to count the mRNA transcripts present in matched plasma, urine, tumor tissue, and normal tumor adjacent tissue samples. Results: 770 mRNA transcripts related to gene's affecting cancer's progression and metastasis processes were evaluated. Four EV derived mRNA transcripts (ALOX5, RBL2, VEGFA, TLK2) were found specific to urine and tumor tissue samples. Conclusion: Four candidate RCC-specific urine EV biomarkers were identified. However, due to the lack of a true negative control and urine collection techniques, further re-examination is necessary for validation. This study demonstrates the promise of defining disease-specific EV biomarkers in liquid biopsy patient samples.
UR - http://www.scopus.com/inward/record.url?scp=85121429939&partnerID=8YFLogxK
U2 - https://doi.org/10.1016/j.urology.2021.11.002
DO - https://doi.org/10.1016/j.urology.2021.11.002
M3 - Article
C2 - 34793840
SN - 0090-4295
VL - 160
SP - 87
EP - 93
JO - Urology
JF - Urology
ER -